Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Aureotan
2. Auromyose
3. Aurothioglucose, Beta D Isomer
4. Aurothioglucose, Beta-d Isomer
5. Aurothioglucose, Sodium Salt, Beta-d Isomer
6. B Oleosum, Solganal
7. Beta-d Isomer Aurothioglucose
8. Gold 50
9. Gold Thioglucose
10. Gold-50
11. Gold50
12. Oleosum, Solganal B
13. Solganal
14. Solganal B Oleosum
15. Solganol
16. Thioglucose, Gold
17. Thioglucosoaurate
1. 12192-57-3
2. Gold(1+);3,4,5-trihydroxy-6-(hydroxymethyl)oxane-2-thiolate
3. Gold(1+);(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxane-2-thiolate
4. Aurothioglucose Hydrate
5. Ncgc00096015-01
6. Aurothioglucose 80%
7. Spectrum_001866
8. Nsc-759601
9. Dsstox_cid_26013
10. Dsstox_rid_81289
11. Dsstox_gsid_46013
12. Kbioss_002383
13. Spectrum1500132
14. Kbio2_002379
15. Kbio2_004947
16. Kbio2_007515
17. Hms2091k17
18. Pharmakon1600-01500132
19. Tox21_111549
20. Nsc759601
21. Ccg-213700
22. Sbi-0206666.p002
23. Cas-12192-57-3
24. Ab00053375_02
25. 192a573
26. Sr-05000001568
27. Sr-05000001568-1
| Molecular Weight | 392.18 g/mol |
|---|---|
| Molecular Formula | C6H11AuO5S |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 1 |
| Exact Mass | 391.999290 g/mol |
| Monoisotopic Mass | 391.999290 g/mol |
| Topological Polar Surface Area | 91.2 Ų |
| Heavy Atom Count | 13 |
| Formal Charge | 0 |
| Complexity | 160 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
... Aurothioglucose ... /is/ indicated in the treatment of adult or juvenile rheumatoid arthritis. ... /This agent is/ usually used for treating patients who show evidence of continued or additional disease activity despite conservative therapy, e.g., with salicylates (especially aspirin) or other nonsteroidal anti-inflammatory agents, glucocorticoids, etc. /Included in US product labeling/
MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 23rd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2003. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1586
Gold compounds are used in the treatment of these rheumatic conditions / psoriatic arthritis, Felty's syndrome/. /Gold compounds; NOT included in US product labeling/
MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 23rd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2003. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1587
Patients intolerant of parabens may be intolerant of parenteral aurothioglucose, which may contain propylparaben.
MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 23rd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2003. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1587
Patients sensitive to sesame products may also be sensitive to the sesame oil vehicle of parenteral aurothioglucose.
MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 23rd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2003. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1587
Dermatitis is the most common reaction. Pruritus should be considered a warning signal of an impending cutaneous reaction. Erythema and occasionally the more severe reactions such as popular, vesicular, and exfoliative dermatitis leading to alopecia and shedding of the nails may occur. Chrysiasis (gray-to-blue pigmentation) has been reported, especially in photo-exposed areas. Gold dermatitis may be aggravated by exposure to sunlight, or an actinic rash may develop.
Medical Economics Co; Physicians Desk Reference 50th ed p. 2388 (1996)
Stomatitis is the second most common adverse reaction. Shallow ulcers on the buccal membranes, on the borders of the tongue and on the palate, diffuse glossitis , or gingivitis may be preceded by the sensation of metallic taste. Careful oral hygiene is recommended. Inflammation of the upper respiratory tract, pharyngitis, gastritis, colitis, tracheitis, and vaginitis have also been reported. Conjunctivitis is rare.
Medical Economics Co; Physicians Desk Reference 50th ed p. 2388 (1996)
For more Drug Warnings (Complete) data for AUROTHIOGLUCOSE (11 total), please visit the HSDB record page.
Antirheumatic Agents
Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)
M - Musculo-skeletal system
M01 - Antiinflammatory and antirheumatic products
M01C - Specific antirheumatic agents
M01CB - Gold preparations
M01CB04 - Aurothioglucose
The true potential of gold compounds, including ... aurothioglucose, to cumumulate has not been clearly defined, but it is clear that substantially larger amounts of gold are retained in the body during therapy with parenteral gold compounds than during therapy with auranofin.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 2848
Small amounts of gold have been shown to be distributed into milk in women receiving aurothioglucose ... .
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 2848
Gold is absorbed from injection sites, reaching peak concentration in blood in four to six hours. Following single intramuscular injection of 50 mg Solganal /aurothioglucose/ suspension in each of two patients, peak serum levels were about 235 mcg/dl in one patient and 450 mcg/dl in the other. In plasma, 95% is bound to albumin fraction. Approximately 70% of the gold is eliminated in the urine and approximately 30% in the feces. When a standard weekly treatment schedule is followed, approximately 40% of the administered dose is excreted each week, and the remainder is excreted over a longer period.
Medical Economics Co; Physicians Desk Reference 50th ed p. 2388 (1996)
After the initial injection, the serum level of gold rises sharply and declines over the next week. Peak levels with aqueous preparations are higher and decline faster than those with oily preparations. Weekly administration produces a continuous rise in the basal value for several months, after which the serum level becomes relatively stable. After a standard weekly dose, considerable individual variation in the levels of gold has been found. A steady decline in gold levels occurs when the interval between injections is lengthened, and small amounts may be found in the serum for months after discontinuance of therapy. The incidence of toxic reactions is apparently unrelated to the cumulative body content of gold.
Medical Economics Co; Physicians Desk Reference 50th ed p. 2388 (1996)
For more Absorption, Distribution and Excretion (Complete) data for AUROTHIOGLUCOSE (6 total), please visit the HSDB record page.
For a patient receiving gold sodium thiomalate the principal gold species in the urine is [Au(CN)2]-, which is also seen in a low molecular weight infiltrate of the blood. The same compound is also identified in the urine and blood of a patient taking solganol
PMID:8474063 Elder R et al; J Rheumatol. 20 (2): 268-72 (1993)
The biological half-life of gold salts following a single 50 mg dose has been reported to range from 3 to 27 days. Following successive weekly doses, the half-life increases and may be 14 to 40 days after the third dose and up to 168 days after the eleventh weekly dose.
Medical Economics Co; Physicians Desk Reference 50th ed p. 2388 (1996)
The effects of aurothioglucose, on basal and forskolin-activated adenylyl cyclase activity in human total lymphocyte membranes and in membranes of T and B lymphocyte subsets /was studied/. The gold compounds inhibited adenylyl cyclase activity. This inhibitory effect required the presence of both the sulfhydryl ligands and aurous cation. Regulation of lymphocyte adenylyl cyclase by gold compounds represents a potential mode of action of these drugs in rheumatic disease.
PMID:1642653 Lazarevic M et at; Arthritis Rheum 35 (8): 857-64 (1992)
Transcription factor NF-kappaB controls the expression of a number of genes including those for cell adhesion molecules such as E-selectin, ICAM- 1 and VCAM- 1. These cell adhesion molecules are known to play important roles in a critical step of tumor metastasis; the arrest of tumor cells on the venous or capillary bed of the target organ. NF-kappaB is activated by extracellular signals such as those elicited by the proinflammatory cytokines, TNF and IL-1. The adhesion of tumor cells to IL-1 beta-treated HUVEC /human umbilical vein endothelial cells/ was inhibited by gold compounds such as aurothioglucose.
Tozawa K et al; Cancer Lett. 196 (1): 93-100
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
67
PharmaCompass offers a list of Aurothioglucose API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Aurothioglucose manufacturer or Aurothioglucose supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Aurothioglucose manufacturer or Aurothioglucose supplier.
PharmaCompass also assists you with knowing the Aurothioglucose API Price utilized in the formulation of products. Aurothioglucose API Price is not always fixed or binding as the Aurothioglucose Price is obtained through a variety of data sources. The Aurothioglucose Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Aurothioglucose manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aurothioglucose, including repackagers and relabelers. The FDA regulates Aurothioglucose manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aurothioglucose API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Aurothioglucose supplier is an individual or a company that provides Aurothioglucose active pharmaceutical ingredient (API) or Aurothioglucose finished formulations upon request. The Aurothioglucose suppliers may include Aurothioglucose API manufacturers, exporters, distributors and traders.
Aurothioglucose Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aurothioglucose GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Aurothioglucose GMP manufacturer or Aurothioglucose GMP API supplier for your needs.
A Aurothioglucose CoA (Certificate of Analysis) is a formal document that attests to Aurothioglucose's compliance with Aurothioglucose specifications and serves as a tool for batch-level quality control.
Aurothioglucose CoA mostly includes findings from lab analyses of a specific batch. For each Aurothioglucose CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aurothioglucose may be tested according to a variety of international standards, such as European Pharmacopoeia (Aurothioglucose EP), Aurothioglucose JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aurothioglucose USP).
